BioCardia Announces Timing For Prespecified Data Safety Monitoring Board Report on Pivotal CardiAMP Heart Failure Trial

March 12, 2020

Company to Host a Conference Call with National Co-Principal Investigators on  March 31, 2020 at 4:15 p.m. ET

Fourth Quarter 2019 Financial Results to be Issued March 30, 2020

SAN CARLOS, Calif. – BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) is expected to report on a prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which will be available for release on Tuesday, March 31, 2020. The report will be based on a review of all available safety data from all patients randomized in the trial. To date, 72 patients have been enrolled in the trial.

BioCardia will host a conference call/webcast to provide updates on the CardiAMP Heart Failure Trial featuring national co-principal investigators, Amish Raval, MD, of the University of Wisconsin and Carl Pepine, MD, of the University of Florida, Gainesville, on Tuesday, March 31 at 4:15 p.m. ET.  

To participate in this conference call, dial 1-877-270-2148.  To access a live webcast of the call, please visit: A replay of the webcast will be available for a limited time on the BioCardia website following the presentation.

The ongoing multi-center, double-blinded, randomized (3:2), sham-controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. The trial’s primary efficacy endpoint is a composite of Six Minute Walk distance at 12 months’ post-treatment (a measure of a patient’s exercise capacity), which  incorporates the impact of Major Adverse Cardiac Events (MACE) and other clinically meaningful events. Secondary efficacy endpoints include quality of life as measured by the Minnesota Heart Failure Quality of Life self-assessment, and superiority relative to MACE and survival.

The company will be reporting fourth quarter 2019 financial results on the prior day, Monday, March 30.

About the CardiAMP Therapy Program
CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally-invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Heart Failure Trial is the first multi-center clinical trial of a stem cell therapy to prospectively screen for stem cell therapeutic potency in order to improve patient outcomes.   

About BioCardia®
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP™ and CardiALLO™ cell therapies are the Company’s biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ Biotherapeutic Delivery System and the Morph® steerable guide and sheath catheter portfolio, including the new AVANCE™ Steerable Introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Forward Looking Statements:
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-Q filed with the Securities and Exchange Commission on November 19, 2019, including under the caption titled “Risk Factors.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

David McClung, Chief Financial Officer, (650) 226-0120

Michelle McAdam, Chronic Communications, Inc., (310) 545-6654


Have questions?
: (800) 624-1179
Have questions?

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.